A Multicenter, Randomized, Open-label, Phase 2 Study Evaluating the Safety and Efficacy of BMS-986504 Monotherapy in Participants with Advanced or Metastatic Non-small Cell LungmCancer (NSCLC) with Homozygous MTAP Deletion After Progression on Prior Therapies
Phase: Phase II clinical trials
Principal Investigator: Dott.ssa Proto Claudia
Main Facility: Oncologia Medica Toraco-Polmonare
Drug: BMS-986504
Pathologies: Lung cancer
ClinicalTrials.gov: Read the details about clinical trials
Study CA2400009 is a global, Phase 2 clinical trial in patients with advanced MTAP-deleted non-cell lung cancer (NSCLC), which aims to evaluate the safety and efficacy of a new drug called BMS-986504. The study is divided into two consecutive parts:
Part 1 (Dose Selection): Participants are randomly assigned (1:1 randomization) to one of two treatment arms in order to compare two different doses of the study drug.
Part 2 (Dose Expansion): In this second phase, after analyzing the data from Part 1, all new participants will exclusively receive the single dose that has been selected as optimal.
At the end of the treatment, a follow-up period is planned for all participants, which includes safety monitoring (28 days after the last dose) and a subsequent long-term survival assessment for up to a maximum of 3 years.
Last update: 13/07/2026